TABLE 4.
The chi-square test of the relation between risk score and clinical features in GSE14520 cohort.
| Clinical feature | Risk score |
c2 | p | |
| High risk n(%) | Low risk n(%) | |||
| Age | 1.162 | 0.281 | ||
| >65 | 9(47.37%) | 10(52.63%) | ||
| ≤65 | 119(60.10%) | 79(39.90%) | ||
| Gender | 0.39 | 0.533 | ||
| MALE | 113(59.79%) | 76(40.21%) | ||
| FEMALE | 15(53.57%) | 13(46.43%) | ||
| ALT | 0.666 | 0.415 | ||
| >50U/L | 56(62.22%) | 34(37.78%) | ||
| ≤50 U/L | 72(56.69%) | 55(43.31%) | ||
| Main Tumor Size | 6.126 | 0.013 | ||
| >5 cm | 54(70.13%) | 23(29.87%) | ||
| ≤5 cm | 74(52.86%) | 66(47.14%) | ||
| Multitumor | 1.205 | 0.272 | ||
| NO | 97(57.06%) | 73(42.94%) | ||
| YES | 31(65.96%) | 16(34.04%) | ||
| Stage TNM | 13.417 | <0.001 | ||
| I–II | 88(52.38%) | 80(47.62%) | ||
| III–IV | 40(81.63%) | 9(18.37%) | ||
| Cirrhosis | 11.241 | <0.001 | ||
| YES | 125(60%) | 75(40%) | ||
| NO | 3(17.65%) | 14(82.35%) | ||
| Stage BCLC | ||||
| 0-A | 88(53.33%) | 77(46.67%) | 9.095 | 0.003 |
| B-C | 40(76.92%) | 12(23.08%) | ||
| CLIP_Score | ||||
| ≥2 | 33(68.75%) | 15(31.25%) | 2.429 | 0.119 |
| <2 | 95(56.21%) | 74(43.79%) | ||
| AFP | 1.103 | 0.294 | ||
| >300 ng/ml | 61(62.89%) | 36(37.11%) | ||
| ≥300 ng/ml | 67(55.83) | 53(44.17%) | ||